2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Venous Thromboembolism
16
Venous Thrombosis
12
Pulmonary Embolism
11
Neoplasms
10
Thrombosis
4
Thromboembolism
4
Pancreatic Neoplasms
4
Lung Neoplasms
4
Multiple Myeloma
3
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Interventions
Cisplatin
161
Fluorouracil
135
Paclitaxel
127
Radiotherapy
125
Oxaliplatin
88
Carboplatin
72
Docetaxel
71
Irinotecan
60
pembrolizumab
57
Leucovorin
57
Capecitabine
57
Radiation
48
Esophagectomy
44
Surgical Procedures, Operative
42
Drug Therapy
38
Neoadjuvant Therapy
28
Cetuximab
25
Nivolumab
24
Bevacizumab
21
camrelizumab
20
Trastuzumab
20
S 1 (combination)
19
Chemoradiotherapy
19
Magnetic Resonance Spectroscopy
18
Epirubicin
16
Albumin-Bound Paclitaxel
16
Blood Specimen Collection
15
tislelizumab
14
Taxes
14
Radiotherapy, Intensity-Modulated
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Dalteparin
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled